Information Provided By:
Fly News Breaks for September 13, 2019
CLRB
Sep 13, 2019 | 08:41 EDT
Roth Capital analyst Jerry Isaacson initiated Cellectar Biosciences with a Buy rating and $11 price target, saying he expects numerous efficacy readouts before the end of 2019, in R/R multiple myeloma and R/R diffuse large B-cell lymphoma. Cellectar has successfully brought CLR 131 through clinical trials targeting hematological malignancies and has a clear pathway to approval for the treatment of late-stage multiple myeloma, Isaacson tells investors in a research note.
News For CLRB From the Last 2 Days
CLRB
Mar 28, 2024 | 07:43 EDT
Oppenheimer raised the firm's price target on Cellectar Biosciences to $12 from $11 and keeps an Outperform rating on the shares. The firm notes that on Wednesday, Cellectar reported year-end results following January's impressive interim readout for the pivotal iopofosine I-131 study in WM. Management remains confident in its second half of 2024 NDA filing goal, with an approval under fast-track possible mid-year 2025. Updated data anticipated in May, which Oppenheimer expects to validate the positive interim read. The firm's discussion with management highlighted the opportunity for a broader label, supporting Oppenheimer's confidence in the market.